pioglitazone and Hirsutism
pioglitazone has been researched along with Hirsutism in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 9.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
"We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome." | 9.16 | Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012) |
"Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment." | 9.14 | Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. ( Aigner, E; Bachofner, N; Datz, C; De Geyter, C; Hohla, F; Klein, K; Patsch, W, 2009) |
"To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 9.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
"Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
" PCOS women were treated with pioglitazone 30 mg/day and at the beginning and after 6 months of treatment were evaluated: menstrual cycle trend, hirsutism and acne, total cholesterolemia and HDL, triglyceridemia, fibrinogenemia, C-reactive protein, oral glucose tolerance test, glycated hemoglobin, FSH, LH, 17OH-progesterone, 17β-estradiol, free and total testosterone, SHBG, DHEA-S, Δ4-androstenedione and adiponectin." | 5.19 | Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. ( Artenisio, AC; Benvenga, S; Borrielli, I; Bruno, LM; Giunta, L; La Marca, A; Pizzo, A; Stabile, G; Volpe, A, 2014) |
"We designed a study, involving 52 patients of 19-36 years of age, to test the pioglitazone in women with polycystic ovary syndrome." | 5.16 | Pioglitazone reduces central obesity in polycystic ovary syndrome women. ( Asadipooya, K; Kalantar-Hormozi, M; Nabipour, I, 2012) |
"Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment." | 5.14 | Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. ( Aigner, E; Bachofner, N; Datz, C; De Geyter, C; Hohla, F; Klein, K; Patsch, W, 2009) |
"To investigate the effectiveness and safety of pioglitazone (45 mg/day) on clinical and endocrine-metabolic features of polycystic ovary syndrome (PCOS), we studied 18 obese PCOS patients, classified as normoinsulinaemic (N-PCOS, n = 6) and hyperinsulinaemic (H-PCOS, n = 12) according to their insulin secretion." | 5.10 | Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. ( Ciampelli, M; Giuliani, M; Guido, M; Lanzone, A; Leoni, F; Perri, C; Romualdi, D, 2003) |
"Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
Research
Studies (8)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ibáñez, L | 3 |
Del Río, L | 1 |
Díaz, M | 2 |
Sebastiani, G | 1 |
Pozo, ÓJ | 1 |
López-Bermejo, A | 2 |
de Zegher, F | 3 |
Ong, KK | 1 |
Dunger, DB | 1 |
Stabile, G | 1 |
Borrielli, I | 1 |
Artenisio, AC | 1 |
Bruno, LM | 1 |
Benvenga, S | 1 |
Giunta, L | 1 |
La Marca, A | 1 |
Volpe, A | 1 |
Pizzo, A | 1 |
Gallego-Escuredo, JM | 1 |
Villarroya, F | 1 |
Aigner, E | 1 |
Bachofner, N | 1 |
Klein, K | 1 |
De Geyter, C | 1 |
Hohla, F | 1 |
Patsch, W | 1 |
Datz, C | 1 |
Asadipooya, K | 1 |
Kalantar-Hormozi, M | 1 |
Nabipour, I | 1 |
Du, Q | 1 |
Wang, YJ | 1 |
Yang, S | 1 |
Wu, B | 1 |
Han, P | 1 |
Zhao, YY | 1 |
Romualdi, D | 1 |
Guido, M | 1 |
Ciampelli, M | 1 |
Giuliani, M | 1 |
Leoni, F | 1 |
Perri, C | 1 |
Lanzone, A | 1 |
Reviews
1 review available for pioglitazone and Hirsutism
Article | Year |
---|---|
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
Trials
6 trials available for pioglitazone and Hirsutism
Article | Year |
---|---|
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
Topics: Adiponectin; Adolescent; C-Reactive Protein; Female; Fibrinogen; Hirsutism; Humans; Hyperandrogenism | 2014 |
Effects of ethinylestradiol-cyproterone acetate vs. pioglitazone-flutamide-metformin on plasma FGF21 levels in adolescent girls with androgen excess.
Topics: Adolescent; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Fibroblast Growth Fac | 2016 |
Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
Topics: Adipokines; Adult; Area Under Curve; Blood Glucose; Double-Blind Method; Female; Hirsutism; Humans; | 2009 |
Pioglitazone reduces central obesity in polycystic ovary syndrome women.
Topics: Adult; Body Mass Index; Body Weight; Female; Hirsutism; Humans; Hypoglycemic Agents; Intra-Abdominal | 2012 |
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Acne Vulgaris; Adolescent; Adult; Androgens; Androstenedione; Body Con | 2003 |
Other Studies
1 other study available for pioglitazone and Hirsutism
Article | Year |
---|---|
Hyperinsulinaemic androgen excess in adolescent girls.
Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human | 2014 |